Creatinine- and cystatin C-based estimated glomerular filtration rate slopes for the prediction of kidney outcome: a comparative retrospective study.
Creatinine
/ blood
Cystatin C
/ blood
Disease Progression
Female
Glomerular Filtration Rate
Humans
Kidney Failure, Chronic
/ diagnosis
Male
Middle Aged
Outcome and Process Assessment, Health Care
Prognosis
Proportional Hazards Models
Renal Insufficiency, Chronic
/ blood
Republic of Korea
/ epidemiology
Retrospective Studies
Risk Factors
Chronic kidney disease (CKD)
Disease progression
Estimated glomerular filtration rate (eGFR)
GFR slope
Renal outcome
Serum creatinine
Serum cystatin C
Journal
BMC nephrology
ISSN: 1471-2369
Titre abrégé: BMC Nephrol
Pays: England
ID NLM: 100967793
Informations de publication
Date de publication:
11 06 2019
11 06 2019
Historique:
received:
01
05
2018
accepted:
30
05
2019
entrez:
13
6
2019
pubmed:
13
6
2019
medline:
29
9
2020
Statut:
epublish
Résumé
Many studies have evaluated the usefulness of creatinine- (eGFRcr) and cystatin C-based estimated glomerular filtration rate (eGFRcys) at specific time points in predicting renal outcome. This study compared the performance of both eGFR changing slopes in identifying patients at high risk of end-stage renal disease (ESRD). From 2012 to 2017, patients with more than three simultaneous measurements of serum creatinine and cystatin C for 1 year were identified. Rapid progression was defined as eGFR slope < - 5 mL/min/1.73 m Overall, 1323 patients were included. The baseline eGFRcr and eGFRcys were 39 (27-48) and 38 (27-50) mL/min/1.73 m Both eGFR slopes were associated with future ESRD risk. The eGFRcr slope was comparable with the eGFRcys slope in predicting kidney outcome.
Sections du résumé
BACKGROUND
Many studies have evaluated the usefulness of creatinine- (eGFRcr) and cystatin C-based estimated glomerular filtration rate (eGFRcys) at specific time points in predicting renal outcome. This study compared the performance of both eGFR changing slopes in identifying patients at high risk of end-stage renal disease (ESRD).
METHODS
From 2012 to 2017, patients with more than three simultaneous measurements of serum creatinine and cystatin C for 1 year were identified. Rapid progression was defined as eGFR slope < - 5 mL/min/1.73 m
RESULTS
Overall, 1323 patients were included. The baseline eGFRcr and eGFRcys were 39 (27-48) and 38 (27-50) mL/min/1.73 m
CONCLUSIONS
Both eGFR slopes were associated with future ESRD risk. The eGFRcr slope was comparable with the eGFRcys slope in predicting kidney outcome.
Identifiants
pubmed: 31185945
doi: 10.1186/s12882-019-1403-1
pii: 10.1186/s12882-019-1403-1
pmc: PMC6558736
doi:
Substances chimiques
Cystatin C
0
Creatinine
AYI8EX34EU
Types de publication
Comparative Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
214Références
Ann Intern Med. 1999 Mar 16;130(6):461-70
pubmed: 10075613
Kidney Int. 2004 Apr;65(4):1416-21
pubmed: 15086483
N Engl J Med. 2004 Sep 23;351(13):1296-305
pubmed: 15385656
J Am Soc Nephrol. 2005 May;16(5):1404-12
pubmed: 15788478
Ann Intern Med. 2005 Apr 5;142(7):497-505
pubmed: 15809461
N Engl J Med. 2005 May 19;352(20):2049-60
pubmed: 15901858
Kidney Int. 2006 Jan;69(2):399-405
pubmed: 16408133
N Engl J Med. 2006 Jun 8;354(23):2473-83
pubmed: 16760447
Ann Intern Med. 2006 Aug 15;145(4):237-46
pubmed: 16908914
Scand J Clin Lab Invest. 2007;67(5):560-7
pubmed: 17763193
J Am Soc Nephrol. 2007 Oct;18(10):2749-57
pubmed: 17855641
Clin J Am Soc Nephrol. 2008 Mar;3(2):348-54
pubmed: 18235143
Diabetes Care. 2008 May;31(5):971-3
pubmed: 18319326
Kidney Int. 2009 Mar;75(6):652-60
pubmed: 19119287
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Am Soc Nephrol. 2009 Dec;20(12):2625-30
pubmed: 19892934
J Am Soc Nephrol. 2010 Nov;21(11):1961-9
pubmed: 20947634
Am J Kidney Dis. 2011 Jun;57(6):863-72
pubmed: 21420772
JAMA. 2011 Apr 20;305(15):1545-52
pubmed: 21482744
Clin J Am Soc Nephrol. 2011 Aug;6(8):1879-86
pubmed: 21685022
J Am Soc Nephrol. 2012 Feb;23(2):351-9
pubmed: 22173699
Am J Kidney Dis. 2012 Apr;59(4):495-503
pubmed: 22221483
Clin Chem. 2012 Apr;58(4):680-9
pubmed: 22311920
Am J Kidney Dis. 2012 Apr;59(4):475-7
pubmed: 22444489
Cell Res. 2012 Aug;22(8):1210-1
pubmed: 22525335
Kidney Int. 2012 Sep;82(5):589-97
pubmed: 22622493
N Engl J Med. 2012 Jul 5;367(1):20-9
pubmed: 22762315
Nephrol Dial Transplant. 2012 Oct;27(10):3835-43
pubmed: 22764191
Kidney Int. 2013 Jun;83(6):1169-76
pubmed: 23423253
Lancet. 2013 Jul 13;382(9887):158-69
pubmed: 23727165
N Engl J Med. 2013 Sep 5;369(10):932-43
pubmed: 24004120
Clin Chem. 2014 Jul;60(7):974-86
pubmed: 24829272
J Am Soc Nephrol. 2015 Aug;26(8):1982-9
pubmed: 25527647
Arch Pathol Lab Med. 2015 Jul;139(7):888-93
pubmed: 25884370
Curr Opin Nephrol Hypertens. 2015 May;24(3):295-300
pubmed: 26066476
Clin Chem. 2015 Oct;61(10):1265-72
pubmed: 26240296
J Am Soc Nephrol. 2016 Aug;27(8):2447-55
pubmed: 26657867
Clin Exp Nephrol. 2016 Jun;20(3):379-93
pubmed: 26728745
PLoS Med. 2017 Oct 10;14(10):e1002400
pubmed: 29016597